Who are DMARDs or Biologics's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SARILUMAB, Ro-Actemra, tocilizumab [RoActemra/Actemra], Placebo to tocilizumab, Tocilizumab(400mg), Actemra(EU-licensed).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dmards-or-biologics.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

DMARDs or Biologics — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DMARDs or Biologics (DMARDs or Biologics) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biologic DMARD. Area: Rheumatology.

phase 2 Biologic DMARD IL-6R Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

DMARDs or Biologics (DMARDs or Biologics) — Pfizer. T-cell co-stimulation inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DMARDs or Biologics TARGET	DMARDs or Biologics	Pfizer	phase 2	Biologic DMARD	IL-6R
SARILUMAB	SARILUMAB		marketed	Interleukin-6 Receptor Antagonist [EPC]	IL-6 receptors (sIL-6R and mIL-6R)	2017-01-01
Ro-Actemra	Ro-Actemra	Medical University of Vienna	marketed	IL-6 receptor antagonist	IL-6R (Interleukin-6 receptor)
tocilizumab [RoActemra/Actemra]	tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	marketed	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)
Placebo to tocilizumab	Placebo to tocilizumab	Hoffmann-La Roche	marketed	IL-6 receptor antagonist	IL-6 receptor (IL-6R)
Tocilizumab(400mg)	Tocilizumab(400mg)	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	marketed	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)
Actemra(EU-licensed)	Actemra(EU-licensed)	Bio-Thera Solutions	phase 3	IL-6 receptor antagonist	IL-6R (Interleukin-6 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biologic DMARD class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DMARDs or Biologics — Competitive Intelligence Brief. https://druglandscape.com/ci/dmards-or-biologics. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing